Early investigational drugs for hearing loss

Bibliography

• Available from: http://www.chchearing.org/about-hearing-loss/facts-about-hearing-loss
   Google Scholar
• Available from: http://www.hear-it.org/2050-twice-many-hearing-loss
   Google Scholar
• Available from: www.asha.org
   Google Scholar
• Available from: https://www.nidcd.nih.gov/health/hearing/pages/presbycusis.aspx
   Google Scholar
• Clinical Trials.gov. Available from: www.clinicaltrials.gov
   Google Scholar
• PubMed Database. Available from: www.pubmed.gov
   Google Scholar
• Riva C, Donadieu E, Magnan J, et al. Age-related hearing loss in CD/1 mice is associated to ROS formation and HIF target proteins up-regulation in the cochlea. Exp Gerontol 2007;42(4):327–36
   PubMed Web of Science ®Google Scholar
• Hoshino T, Tabuchi K, Nishimura B, et al. Protective role of Nrf2 in age-related hearing loss and gentamicin ototoxicity. Biochem Biophys Res Commun 2011;415(1):94–8
   PubMed Web of Science ®Google Scholar
• Fetoni AR, De Bartolo P, Eramo SL, et al. Noise-induced hearing loss (NIHL) as a target of oxidative stress-mediated damage: cochlear and cortical responses after an increase in antioxidant defense. J Neurosci 2013;33(9):4011–23
   PubMed Web of Science ®Google Scholar
• Seidman MD, Tang W, Bai VU, et al. Resveratrol decreases noise-induced cyclooxygenase-2 expression in the rat cochlea. Otolaryngol Head Neck Surg 2013;148(5):827–33
   PubMed Web of Science ®Google Scholar
• Rybak LP, Mukherjea D, Jajoo S, et al. Cisplatin ototoxicity and protection: clinical and experimental studies. Tohoku J Exp Med 2009;219(3):177–86
   PubMed Web of Science ®Google Scholar
• Wu WJ, Sha SH, Schacht J. Recent advances in understanding aminoglycoside ototoxicity and its prevention. Audiol Neurootol 2002;7(3):171–4
   PubMed Web of Science ®Google Scholar
• Parnham MJ, Kindt S. A novel biologically active seleno-organic compound-III. Effects of PZ 51 (ebselen) on glutathione peroxidase and secretory activities of mouse macrophages. Biochem Pharmacol 1984;33:3247–50
   PubMed Web of Science ®Google Scholar
• Parnham MJ, Graf E. Seleno-organic compounds and the therapy of hydroperoxide-linked pathological conditions. Biochem Pharmacol 1987;36:3095–102
   PubMed Web of Science ®Google Scholar
• Masumoto H, Kissner R, Koppenol WH, et al. Kinetic study of the reaction of ebselen with peroxynitrite. FEBS Lett 1996;398:179–82
   PubMed Web of Science ®Google Scholar
• Kil J, Pierce C, Tran H, et al. Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hear Res 2007;226:44–51
   PubMed Web of Science ®Google Scholar
• Lynch ED, Gu R, Pierce C, et al. Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen. Hear Res 2005;201:81–9
   PubMed Web of Science ®Google Scholar
• Geier DA, Geier MR. A clinical and laboratory evaluation of methionine cycle-transsulfuration and androgen pathway markers in children with autistic disorders. Horm Res 2006;66(4):182–8
   PubMed Web of Science ®Google Scholar
• Kopke RD, Weisskopf PA, Boone JL, et al. Reduction of noise-induced hearing loss using L-NAC and salicylate in the chinchilla. Hear Res 2000;149(1-2):138–46
   PubMed Web of Science ®Google Scholar
• Yoo J, Hamilton SJ, Angel D, et al. Cisplatin otoprotection using transtympanic L-N-acetylcysteine: a pilot randomized study in head and neck cancer patients. Laryngoscope 2014;124(3):E87–94
   PubMed Web of Science ®Google Scholar
• Gilles A, Ihtijarevic B, Wouters K, et al. Using prophylactic antioxidants to prevent noise-induced hearing damage in young adults: a protocol for a double-blind, randomized controlled trial. Trials 2014;15:110
   PubMed Web of Science ®Google Scholar
• Hoffer ME, Balaban C, Slade MD, et al. Amelioration of acute sequelae of blast induced mild traumatic brain injury by N-acetyl cysteine: a double-blind, placebo controlled study. PLoS One 2013;8(1):e54163
   PubMedGoogle Scholar
• Sooriyaarachchi M, Narendran A, Gailer J. N-acetyl-L-cysteine modulates the metabolism of cis-platin in human plasma in vitro. Metallomics 2013(3):197–207
   PubMed Web of Science ®Google Scholar
• Lin CY, Wu JL, Shih TS, et al. N-Acetyl-cysteine against noise-induced temporary threshold shift in male workers. Hear Res 2010;269(1-2):42–7
   PubMed Web of Science ®Google Scholar
• Tokgoz B, Ucar C, Kocyigit I, et al. Protective effect of N-acetylcysteine from drug-induced ototoxicity in uraemic patients with CAPD peritonitis. Nephrol Dial Transplant 2011;26(12):4073–8
   PubMed Web of Science ®Google Scholar
• Low WK, Sun L, Tan MG, et al. L-N-Acetylcysteine protects against radiation-induced apoptosis in a cochlear cell line. Acta Otolaryngol 2008;128(4):440–5
   PubMed Web of Science ®Google Scholar
• Feghali JG, Liu W, Van De Water TR. L-n-acetyl-cysteine protection against cisplatin-induced auditory neuronal and hair cell toxicity. Laryngoscope 2001;111(7):1147–55
   PubMed Web of Science ®Google Scholar
• Choe WT, Chinosornvatana N, Chang KW. Prevention of cisplatin ototoxicity using transtympanic N-acetylcysteine and lactate. Otol Neurotol 2004;25(6):910–15
   PubMed Web of Science ®Google Scholar
• Nader ME, Théorêt Y, Saliba I. The role of intratympanic lactate injection in the prevention of cisplatin-induced ototoxicity. Laryngoscope 2010;120(6):1208–13
   PubMed Web of Science ®Google Scholar
• Sanli A, Aydin S, Sarisoy ZA, et al. The protective effect of dexamethasone and lactate against cisplatin-induced ototoxicity. Turk J Med Sci 2011;41(3):467–74
   Web of Science ®Google Scholar
• Munguia R, Sahmkow SI, Funnell WR, et al. Transtympanic Ringer’s lactate application in the prevention of cisplatinum-induced ototoxicity in a chinchilla animal model. Otolaryngol Head Neck Surg 2010;143:134–14
   PubMed Web of Science ®Google Scholar
• Fukaya H, Kanno H. Experimental studies of the protective effect of ginkgo biloba extract (GBE) on cisplatin-induced toxicity in rats. Nihon Jibiinkoka Gakkai Kaiho 1999;102(7):907–17
   PubMedGoogle Scholar
• Tian CJ, Kim YJ, Kim SW, et al. A combination of cilostazol and Ginkgo biloba extract protects against cisplatin-induced Cochleo-vestibular dysfunction by inhibiting the mitochondrial apoptotic and ERK pathways. Cell Death Dis 2013;4:e509
   PubMedGoogle Scholar
• Xu O, Lu H, Li PQ, et al. Effect of combination of Ginkgo leaf extract and deferoxamine in preventing and treating ototoxicity of cisplatin. Zhongguo Zhong Xi Yi Jie He Za Zhi 2004;24(10):915–18
   PubMedGoogle Scholar
• Huang X, Whitworth CA, Rybak LP. Ginkgo biloba extract (EGb 761) protects against cisplatin-induced ototoxicity in rats. Otol Neurotol 2007;28(6):828–33
   PubMed Web of Science ®Google Scholar
• Cakil B, Basar FS, Atmaca S, et al. The protective effect of Ginkgo biloba extract against experimental cisplatin ototoxicity: animal research using distortion product otoacoustic emissions. J Laryngol Otol 2012;126(11):1097–101
   PubMed Web of Science ®Google Scholar
• Burschka MA, Hassan HA, Reineke T, et al. Effect of treatment with Ginkgo biloba extract EGb 761 (oral) on unilateral idiopathic sudden hearing loss in a prospective randomized double-blind study of 106 outpatients. Eur Arch Otorhinolaryngol 2001;258(5):213–19
   PubMed Web of Science ®Google Scholar
• McFadden SL, Woo JM, Michalak N, Ding D. Dietary vitamin C supplementation reduces noise-induced hearing loss in guinea pigs. Hear Res 2005;202(1-2):200–8
   PubMed Web of Science ®Google Scholar
• Hou F, Wang S, Zhai S, et al. Effects of alpha-tocopherol on noise-induced hearing loss in guinea pigs. Hear Res 2003;179(1-2):1–8
   PubMed Web of Science ®Google Scholar
• Le Prell CG, Hughes LF, Miller JM. Free radical scavenger’s vitamins a, c, and e plus magnesium reduce noise trauma. Free Radic Biol Med 2007;42:1454–63
   PubMed Web of Science ®Google Scholar
• Kinoshita M, Sakamoto T, Kashio A, et al. Age-related hearing loss in Mn-SOD heterozygous knockout mice. Oxid Med Cell Longev 2013;2013:325702
   PubMed Web of Science ®Google Scholar
• Le Prell CG, Yagi M, Kawamoto K, et al. Chronic excitotoxicity in the guinea pig cochlea induces temporary functional deficits without disrupting otoacoustic emissions. J Acoust Soc Am 2004;116(2):1044–56
   PubMed Web of Science ®Google Scholar
• Le Prell CG, Johnson AC, Lindblad AC, et al. Increased vitamin plasma levels in Swedish military personnel treated with nutrients prior to automatic weapon training. Noise Health 2011;13(55):432–43
   PubMed Web of Science ®Google Scholar
• Choi YH, Miller JM, Tucker KL, et al. Antioxidant vitamins and magnesium and the risk of hearing loss in the US general population. Am J Clin Nutr 2014;99(1):148–55
   PubMed Web of Science ®Google Scholar
• Kang JW, Choi HS, Kim K, et al. Dietary vitamin intake correlates with hearing thresholds in the olderpopulation: the Korean National Health and Nutrition Examination Survey. Am J Clin Nutr 2014;99(6):1407–13
   PubMed Web of Science ®Google Scholar
• Rybak LP, Husain K, Whitworth C, et al. Dose dependent protection by lipoic acid against cisplatin-induced ototoxicity in rats: antioxidant defense system. Toxicol Sci 1999;47:195–202
   PubMed Web of Science ®Google Scholar
• Kim J, Cho HJ, Sagong B, et al. Alpha-lipoic acid protects against cisplatin-induced ototoxicity via the regulation of MAPKs and proinflammatory cytokines. Biochem Biophys Res Commun 2014;449(2):183–9
   PubMed Web of Science ®Google Scholar
• Seidman MD, Khan MJ, Shirwany N, et al. Biologic activity of mitochondrial metabolites on aging and age-related hearing loss. Am J Otol 2000;21:161–7
   PubMedGoogle Scholar
• Peng W, Hu Y, Zhong Y, et al. Protective roles of alpha-lipoic acid in rat model of mitochondrial DNA4834bp deletion in inner ear. J Huazhong Univ Sci Technolog Med Sci 2010;30(4):514–18
   PubMed Web of Science ®Google Scholar
• Quaranta N, Dicorato A, Matera V, et al. The effect of alpha-lipoic acid on temporary threshold shift in humans: a preliminary study. Acta Otorhinolaryngol Ital 2012;32:380–5
   PubMed Web of Science ®Google Scholar
• Abi-Hachem RN, Zine A, Van De Water TR. The injured cochlea as a target for inflammatory processes, initiation of cell death pathways and application of related otoprotectives strategies. Recent Pat CNS Drug Discov 2010;5(2):147–63
   PubMedGoogle Scholar
• Himeno C, Komeda M, Izumikawa M, et al. Intra-cochlear administration of dexamethasone attenuates aminoglycoside ototoxicity in the guinea pig. Hear Res 2002;67:61–70
   Web of Science ®Google Scholar
• Park SK, Choi D, Russell P, et al. Protective effect of corticosteroid against the cytotoxicity of aminoglycoside otic drops on isolated cochlear outer hair cells. Laryngoscope 2004;114(4):768–71
   PubMed Web of Science ®Google Scholar
• Paksoy M, Ayduran E, Sanli A, et al. The protective effects of intratympanic dexamethasone and vitamin E on cisplatin-induced ototoxicity are demonstrated in rats. Med Oncol 2011;28(2):615–21
   PubMed Web of Science ®Google Scholar
• Filipo R, Attanasio G, Russo FY, et al. Intratympanic steroid therapy in moderate sudden hearing loss: a randomized, triple-blind, placebo-controlled trial. Laryngoscope 2013;123(3):774–8
   PubMed Web of Science ®Google Scholar
• Filipo R, Attanasio G, Russo FY, et al. Oral versus short-term intratympanic prednisolone therapy for idiopathic sudden hearing loss. Audiol Neurootol 2014;19(4):225–33
   PubMed Web of Science ®Google Scholar
• Wu HP, Chou YF, Yu SH, et al. Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otol Neurotol 2011;32(5):774–9
   PubMed Web of Science ®Google Scholar
• Ferri E, Frisina A, Fasson AC, et al. Intratympanic steroid treatment for idiopathic sudden sensorineural hearing loss after failure of intravenous therapy. ISRN Otolaryngol 2012;2012:647271
   Google Scholar
• Raghunandhan S, Agarwal AK, Natarajan K, et al. Effect of intravenous administration of steroids in the management of sudden sensori-neural hearing loss: our experience. Indian J Otolaryngol Head Neck Surg 2013;65(3):229–33
   Web of Science ®Google Scholar
• Trune DR, Kempton JB. Low dose combination steroids control autoimmune mouse hearing loss. J Neuroimmunol 2010;229(1-2):140–5
   PubMed Web of Science ®Google Scholar
• Shafik AG, Elkabarity RH, Thabet MT, et al. Effect of intratympanic dexamethasone administration on cisplatin-induced ototoxicity in adult guinea pigs. Auris Nasus Larynx 2013;40(1):51–60
   PubMed Web of Science ®Google Scholar
• Murphy D, Daniel SJ. Intratympanic dexamethasone to prevent cisplatin ototoxicity: a guinea pig model. Otolaryngol Head Neck Surg 2011;145(3):452–7
   PubMed Web of Science ®Google Scholar
• Hill GW, Morest DK, Parham K. Cisplatin-induced ototoxicity: effect of intratympanic dexamethasone injections. Otol Neurotol 2008;29(7):1005–11
   PubMed Web of Science ®Google Scholar
• Daldal A, Odabasi O, Serbetcioglu B. The protective effect of intratympanic dexamethasone on cisplatin-induced ototoxicity in guinea pigs. Otolaryngol Head Neck Surg 2007;137(5):747–52
   PubMed Web of Science ®Google Scholar
• Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal 2010;3(105):cm1
   PubMed Web of Science ®Google Scholar
• Perrier S, Darakhshan F, Hajduch E. IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde? FEBS Lett 2006;580(27):6289–94
   PubMed Web of Science ®Google Scholar
• Owyang AM, Issafras H, Corbin J, et al. XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1beta-mediated diseases. MAbs 2011;3(1):49–60
   PubMed Web of Science ®Google Scholar
• Zhao R, Zhou H, Su SB. A critical role for interleukin-1beta in the progression of autoimmune diseases. Int Immunopharmacol 2013;17(3):658–69
   PubMed Web of Science ®Google Scholar
• Pathak S, Goldofsky E, Vivas EX, et al. IL-1beta is overexpressed and aberrantly regulated in corticosteroid nonresponders with autoimmune inner ear disease. J Immunol 2011;186(3):1870–9
   PubMed Web of Science ®Google Scholar
• Vambutas A, DeVoti J, Goldofsky E, et al. Alternate splicing of interleukin-1 receptor type II (IL1R2) in vitro correlates with clinical glucocorticoid responsiveness in patients with AIED. PLoS One 2009;4(4):e5293
   PubMed Web of Science ®Google Scholar
• Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006;355(6):581–92
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012;11(8):633–52
   PubMed Web of Science ®Google Scholar
• Kuemmerle-Deschner JB, Lohse P, Koetter I, et al. NLRP3 E311K mutation in a large family with Muckle-Wells syndrome–description of a heterogeneous phenotype and response to treatment. Arthritis Res Ther 2011;13(6):R196
   PubMed Web of Science ®Google Scholar
• Kuemmerle-Deschner JB, Tyrrell PN, Koetter I, et al. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. Arthritis Rheum 2011;63(3):840–9
   PubMed Web of Science ®Google Scholar
• Sibley CH, Plass N, Snow J, et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum 2012;64(7):2375–86
   PubMed Web of Science ®Google Scholar
• Wang J, Van De Water TR, Bonny C, et al. A peptide inhibitor of c-Jun N-terminal kinase protects against both aminoglycoside and acoustic trauma-induced auditory hair cell death and hearing loss. J Neurosci 2003;23:8596–60
   PubMed Web of Science ®Google Scholar
• Arpornchayanon W, Canis M, Ihler F, et al. TNF-alpha inhibition using etanercept prevents noise-induced hearing loss by improvement of cochlear blood flow in vivo. Int J Audiol 2013;52(8):545–52
   PubMed Web of Science ®Google Scholar
• Kaur T, Mukherjea D, Sheehan K, et al. Short interfering RNA against STAT1 attenuates cisplatin-induced ototoxicity in the rat by suppressing inflammation. Cell Death Dis 2011;2:e180
   PubMed Web of Science ®Google Scholar
• Rybak LP, Mukherjea D, Jajoo S, et al. siRNA-mediated knock-down of NOX3: therapy for hearing loss? Cell Mol Life Sci 2012;69(14):2429–34
   PubMed Web of Science ®Google Scholar
• Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391:806–11
   PubMed Web of Science ®Google Scholar
• Tabara H, Yasuda J. Physiological and technological aspects of RNAi. Tanpakushitsu Kakusan Koso 2003;48(4 Suppl):469–79
   PubMedGoogle Scholar
• Mello CC. A conversation with Craig C Mello on the discovery of RNAi. Cell Death Differ 2007;14(12):1981–4
   PubMed Web of Science ®Google Scholar
• Hoerter JHA, Walter NG. Chemical modification resolves the asymmetry of siRNA strand degradation in human blood serum. RNA 2007;13(11):1887–93
   PubMed Web of Science ®Google Scholar
• Maeda Y, Fukushima K, Nishizaki K, et al. In vitro and in vivo suppression of GJB2 expression by RNA interference. Hum Mol Genet 2005;14:1641–50
   PubMed Web of Science ®Google Scholar
• Mukherjea D, Jajoo S, Whitworth C, et al. Short interfering RNA against transient receptor potential vanilloid 1 attenuates cisplatin-induced hearing loss in the rat. J Neurosci 2008;28(49):13056–65
   PubMed Web of Science ®Google Scholar
• Mukherjea D, Jajoo S, Sheehan K, et al. NOX3 NADPH oxidase couples transient receptor potential vanilloid 1 to signal transducer and activator of transcription 1-mediated inflammation and hearing loss. Antioxid Redox Signal 2011;14(6):999–1010
   PubMed Web of Science ®Google Scholar
• Schmitt NC, Rubel EW, Nathanson NM. Cisplatin-induced hair cell death requires STAT1 and is attenuated by epigallocatechin gallate. J Neurosci 2009;29(12):3843–51
   PubMed Web of Science ®Google Scholar
• Heineman TC, Schleiss M, Bernstein DI, et al. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis 2006;193(10):1350–60
   PubMed Web of Science ®Google Scholar
• Available from: http://www.pharmamedtechbi.com/∼/media/Supporting%20Documents/The%20Pink%20Sheet/75/1/Pfizer_research.pdf
   Google Scholar
• Harvey RJ, Yee BK. Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat Rev Drug Discov 2013;12(11):866–85
   PubMed Web of Science ®Google Scholar
• Maciaszczyk K, Lewiński A. Phenotypes of SLC26A4 gene mutations: pendred syndrome and hypoacusis with enlarged vestibular aqueduct. Neuro Endocrinol Lett 2008;29(1):29–36
   PubMed Web of Science ®Google Scholar
• Yang T, Vidarsson H, Rodrigo-Blomqvist S, et al. Transcriptional control of SLC26A4 is involved in Pendred syndrome and nonsyndromic enlargement of vestibular aqueduct (DFNB4). Am J Hum Genet 2007;80(6):1055–63
   PubMed Web of Science ®Google Scholar
• Li X, Sanneman JD, Harbidge DG, et al. SLC26A4 targeted to the endolymphatic sac rescues hearing and balance in Slc26a4 mutant mice. PLoS Genet 2013;9(7):e1003641
   PubMedGoogle Scholar
• Dou H, Xu J, Wang Z, et al. Co-expression of pendrin, vacuolar H+-ATPase alpha4-subunit and carbonic anhydrase II in epithelial cells of the murine endolymphatic sac. J Histochem Cytochem 2004;52(10):1377–84
   PubMed Web of Science ®Google Scholar
• Phillips L, Bitner-Glindzicz M, Lench N, et al. The future role of genetic screening to detect newborns at risk of childhood-onset hearing loss. Int J Audiol 2013;52(2):124–33
   PubMed Web of Science ®Google Scholar
• Hilgert N, Smith RJ, Van Camp G. Forty-six genes causing nonsyndromic hearing impairment: which ones should be analyzed in DNA diagnostics? Mutat Res 2009;681(2-3):189–96
   PubMed Web of Science ®Google Scholar
• Nance WE. The genetics of deafness. Ment Retard Dev Disabil Res Rev 2003;9(2):109–19
   PubMedGoogle Scholar
• Miyagawa M, Nishio SY, Usami S; Consortium DGS. Mutation spectrum and genotype-phenotype correlation of hearing loss patients caused by SLC26A4 mutations in the Japanese: a large cohort study. J Hum Genet 2014;59(5):262–8
   PubMed Web of Science ®Google Scholar
• Nagai J, Takano M. Molecular-targeted approaches to reduce renal accumulation of nephrotoxic drugs. Expert Opin Drug Metab Toxicol 2010;6(9):1125–38
   PubMed Web of Science ®Google Scholar
• Baulac M. Introduction to zonisamide. Epilepsy Res 2006;68(Suppl 2):S3–9
   PubMed Web of Science ®Google Scholar
• Rock DM, Macdonald RL, Taylor CP. Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant. Epilepsy Res 1989;3(2):138–43
   PubMed Web of Science ®Google Scholar
• Ueda Y, Doi T, Tokumaru J, et al. Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Brain Res Mol Brain Res 2003;116(1–2):1–6
   PubMedGoogle Scholar
• Kito M, Maehara M, Watanabe K. Mechanisms of T-type calcium channel blockade by zonisamide. Seizure 1996;5(2):115–19
   PubMed Web of Science ®Google Scholar
• Adamson CL, Reid MA, Davis RL. Opposite actions of brain-derived neurotrophic factor and neurotrophin-3 on firing features and ion channel composition of murine spiral ganglion neurons. J Neurosci 2002;22:1385–96
   PubMed Web of Science ®Google Scholar
• Errington AC, Stohr T, Lees G. Voltage gated ion channels: targets for anticonvulsant drugs. Curr Top Med Chem 2005;5:15–30
   PubMed Web of Science ®Google Scholar
• Fuchs P. The synaptic physiology of cochlear hair cells. Audiol Neurootol 2002;7:40–4
   PubMed Web of Science ®Google Scholar
• Rodriguez-Contreras A, Yamoah EN. Direct measurement of single-channel Ca(2þ) currents in bullfrog hair cells reveals two distinct channel subtypes. J Physiol 2001;534:669–89
   PubMed Web of Science ®Google Scholar
• Schnee ME, Ricci AJ. Biophysical and pharmacological characterization of voltage-gated calcium currents in turtle auditory hair cells. J Physiol 2003;549:697–717
   Google Scholar
• Lacinova L, Klugbauer N, Hofmann F. Low voltage activated calcium channels: from genes to function. Gen Physiol Biophys 2000;19:121–36
   PubMed Web of Science ®Google Scholar
• Perez-Reyes E. Molecular characterization of a novel family of low voltageactivated, T-type, calcium channels. J Bioenerg Biomembr 1998;30:313–18
   PubMed Web of Science ®Google Scholar
• Triggle DJ. L-type calcium channels. Curr Pharm Des 2006;12:443e457
   Google Scholar
• Yunker AM, McEnery MW. Low-voltage-activated (“T-Type”) calcium channels in review. J Bioenerg Biomembr 2003;35:533–75
   PubMed Web of Science ®Google Scholar
• Shen H, Zhang B, Shin JH, et al. Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss. Hear Res 2007;226:52–60
   PubMed Web of Science ®Google Scholar
• Dodson KM, Woodson E, Sismanis A. Intratympanic steroid perfusion for the treatment of Meniere’s disease: a retrospective study. Ear Nose Throat J 2004;83:394–8
   PubMedGoogle Scholar
• MacArthur CJ, Kempton JB, DeGagne J, et al. Control of chronic otitis media and sensorineural hearing loss in C3H/HeJ mice: glucocorticoids vs. mineralocorticoids. Otolaryngol Head Neck Surg 2008;139:646–53
   PubMed Web of Science ®Google Scholar
• Trune DR, Canlon B. Corticosteroid therapy for hearing and balance disorders. Anat Rec 2012;295:1928–43
   Google Scholar
• Canlon B, Meltser I, Johansson P, Tahera Y. Glucocorticoid receptors modulate auditory sensitivity to acoustic trauma. Hear Res 2007;226:61–9
   PubMed Web of Science ®Google Scholar
• Bao J, Hungerford M, Luxmore R, et al. Prophylactic and therapeutic functions of drug combinations against noise-induced hearing loss. Hear Res 2013;304:33–40
   PubMed Web of Science ®Google Scholar
• Available from: http://www.who.int/pbd/deafness/WHO_GE_HL.pdf
   Google Scholar